Figure 6.

Combined efficacy of ganetespib and bardoxolone-methyl in overcoming ENZ-resistance of 22Rv1 cells. Effects of ganetespib (A) or bardoxolone-methyl (B) on 22Rv1 cell viability after 48 or 72 h post-exposure. (C) Multimodal actions of SFN, as both Hsp90 inhibitor and an Nrf2 inducer, implicate the effectiveness of combining ganetespib (G) and bardoxolone-methyl (BM). (D) Effect of G (1.0 µM) and BM (0.25 µM) alone and in combination with ENZ (40 µM) on 22Rv1 cell viability. (E) and (F) Effect of G+BM co-exposure on ENZ-mediated suppression of 22Rv1 cell migration and clonogenic ability, respectively. (E) Fold changes in wound-width at 48 h are shown in 22Rv1 cells and (F) the percentage change in CFUs is shown. In all graphs, error bars represent ± SEM and significant differences between groups are shown as P-values (*P<0.05; **P<0.01).